MDedge Daily News: Where the latest HCV drug combos fit in

The addition of the two latest treatment regimens for hepatitis C essentially closes the circle on treatment of this disease. Don’t shorten therapy for older, sicker cellulitis patients, apixaban and rivaroxaban reversal agent gets FDA approval, and do black women pay a price for hair care products?

Listen to the MDedge Daily News podcast for all the details on today’s top news.






 

The addition of the two latest treatment regimens for hepatitis C essentially closes the circle on treatment of this disease. Don’t shorten therapy for older, sicker cellulitis patients, apixaban and rivaroxaban reversal agent gets FDA approval, and do black women pay a price for hair care products?

Listen to the MDedge Daily News podcast for all the details on today’s top news.






 

The addition of the two latest treatment regimens for hepatitis C essentially closes the circle on treatment of this disease. Don’t shorten therapy for older, sicker cellulitis patients, apixaban and rivaroxaban reversal agent gets FDA approval, and do black women pay a price for hair care products?

Listen to the MDedge Daily News podcast for all the details on today’s top news.